U.S. Treasury Expands Long-Bond Buybacks, Stocks Snap Three-Day Losing Streak
Nashnova编辑部
The U.S. Treasury doubled its long-bond buyback cap to at least $4 billion per operation, pulling the 30-year yield back roughly 10 basis points from a 19-year high — but analysts warn the move may be no more than 'a temporary painkiller.'
What exactly did the Treasury do?
Starting September 9, the per-operation buyback cap for bonds 10 years and longer rises from $2 billion to at least $4 billion, covering two maturity buckets: 10–20 years and 20–30 years.
This means → the Treasury is pulling long-duration paper off the market without expanding the Fed's balance sheet, while issuing more short-term T-bills to replace it.
In plain terms = the government swaps the highest-rate, most volatile long bonds for short-term debt, aiming to push down the long end of the yield curve directly.
How big was the market reaction?
The 30-year Treasury yield fell roughly 10 basis points from a 19-year high of 5.337% to 5.184%. The dollar index dropped to a three-month low of 98.938.
All three major indexes closed modestly higher: Dow +0.22% at 53,463, S&P 500 +0.21% at 7,708, Nasdaq +0.16% at 26,331.
The euro hit $1.1676 (three-month high); the yen traded at 158.32 (pulling back from the closely watched 160 level); the pound reached $1.3603.
How is Wall Street reading this move?
IG analyst Tony Sycamore: "This isn't formal QE or yield-curve control, but it's a clear signal that Washington is ready to fight rising term premium."
Bianco Research president Jim Bianco was blunter: "Wait for Bessent to panic, and bond traders can stop panicking."
This reflects Wall Street's reading of the operation as Treasury Secretary Bessent's deliberate response to the bond sell-off — not a routine buyback.
What are the skeptics saying?
Annex Wealth Management chief strategist Brian Jacobsen called the move "nothing more than a temporary painkiller," arguing the Fed can no longer influence long-term rates and the Treasury is effectively injecting more money-like short-term debt into the economy.
Some analysts note the buyback size is tiny relative to a fiscal deficit that hit $432 billion in July alone — too small to fundamentally shift long-end supply and demand.
In plain terms = the bears' logic is straightforward: the hole is too big, this buyback barely dents it, and swapping long debt for short debt creates its own liquidity risks.
Moderna surged 177% — what happened?
Moderna and Merck jointly announced that their mRNA-based melanoma vaccine succeeded in a Phase III clinical trial, effectively preventing cancer recurrence in high-risk patients.
Moderna soared 176.97% in a single session; Merck gained 13%. The Nasdaq Biotech Index jumped 6.39% to an all-time high.
This means → the market is re-pricing mRNA technology's commercial path from Covid vaccines to cancer treatment. Eli Lilly, Johnson & Johnson, AbbVie, and Merck all hit record closing highs.
Can this rally last?
The latest Fed meeting minutes show a significant number of officials believed a rate hike would be necessary if inflation failed to cool, with several members leaning toward hiking.
The minutes also flagged financial risks from the AI boom — high valuations and leveraged financing expansion could transmit stress into the credit system.
This reflects an unresolved core tension: the Treasury wants to cap long-end yields, but the Fed minutes hint at rate hikes. The tug-of-war between these two forces will determine whether this bounce holds.
Content is for reference only, not financial advice.